MiSeqDx Cystic Fibrosis Clinical Sequencing Assay

该新一代测序实验分析方法经FDA批准,可提供 CFTR基因编码区域的全景视图,有助于囊性纤维化的体外诊断。Read More...

此产品仅在某些选定区域可用。请选择 您希望发货的目的地 ,查看该产品是否在该区域可用。

选择产品

MiSeqDx Cystic Fibrosis Clinical Sequencing Assay (6 runs, 48 samples)

DX-102-1001

Materials Required, Sold Separately
What materials do I need?

TruSeq Index Plate Fixture Kit (2 fixtures)

FC-130-1005

TruSeq Index Plate Fixture & Collar Kit (2 each)

FC-130-1007

产品特色

  • Complete View of the CFTR Gene
    Capture all variants in the protein coding regions and intron/exon boundaries of the CFTR gene
  • Accurate Results
    Deep coverage (> 3,000×) allows detection accuracy with a Positive Agreement (PA) of 99.66%*
  • No Demographic Bias
    Sequencing the CFTR gene removes the bias inherent in existing genotyping panels1

* PA includes polyTG/polyT variants

The MiSeqDx Cystic Fibrosis Clinical Sequencing Assay is the first FDA-cleared in vitro diagnostic (IVD) next-generation sequencing (NGS) test designed to sequence all protein coding regions and intron/exon boundaries of the CFTR gene, including two large deletions, two deep intronic mutations, and indels in homopolymeric regions such as the 2184delA deletion. The assay also automatically detects polyTG/polyT variants. Viewing the CFTR sequence eliminates any bias inherent in existing cystic fibrosis (CF) panels. As a result, the MiSeqDx Cystic Fibrosis Clinical Sequencing Assay can uncover rare mutations not accounted for in standard tests.

Widely adopted next-generation sequencing

The MiSeqDx Cystic Fibrosis Clinical Sequencing Assay provides a fully integrated molecular CF testing solution on the MiSeqDx instrument. Amplify 27 CFTR gene target regions in a single PCR step, and multiplex samples to streamline your workflow. Simply prepare libraries from 250 ng gDNA, load on to the MiSeqDx for sequencing using the Illumina sequencing by synthesis (SBS) chemistry, and analyze with the user-friendly software.

A complete kit for library preparation and sequencing

The MiSeqDx Cystic Fibrosis Clinical Sequencing Assay includes all index primers and reagents needed for library preparation, sample multiplexing, and sequencing in a single kit. MiSeqDx sequencing reagents are packaged in a convenient ready-to-use format, minimizing hands-on time, and increasing uniformity in all tests.

Frequently Purchased Together

规格

Intended Use

The Illumina MiSeqDx Cystic Fibrosis Clinical Sequencing Assay is a targeted sequencing in vitro diagnostic system that re-sequences the protein coding regions and intron/exon boundaries of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in genomic DNA isolated from human peripheral whole blood specimens collected in K2EDTA. The test detects single nucleotide variants and small indels within the region sequenced, and additionally reports on two deep intronic mutations and two large deletions. The test is intended to be used on the Illumina MiSeqDx instrument.

The test is intended to be used as an aid in the diagnosis of individuals with suspected cystic fibrosis (CF). This assay is most appropriate when the patient has an atypical or non-classic presentation of CF or when other mutation panels have failed to identify both causative mutations. The results of this test are intended to be interpreted by a board-certified clinical molecular geneticist or equivalent and should be used in conjunction with other available information including clinical symptoms, other diagnostic tests, and family history. This test is not indicated for use for stand-alone diagnostic purposes, fetal diagnostic testing, preimplantation testing, carrier screening, newborn screening, or population screening.

Contact an Illumina representative for regional availability.

Method-Specific Workflow Example

 

Supporting Data and Figures

 

Related Products

TruSight Cystic Fibrosis

获得FDA认证和CE-IVD认证的新一代测序检测,可在一款产品中提供两种囊性纤维化检测。


TruSeq Custom Amplicon Kit Dx

经验证的、FDA批准和CE-IVD认证的试剂盒让临床实验室得以自行设计可在MiSeqDx和NextSeq 550Dx系统上使用的新一代测序实验分析方法。


References
  1. Hughes EE, Stevens CF, Saavedra-Matiz CA, et al. Clinical sensitivity of cystic fibrosis mutation panels in a diverse population. Human Mutation. 2016;37(2):201-208